Latest Breaking News On - Inverness medical technology inc - Page 1 : vimarsana.com

LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete

LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSan diegoUnited kingdomCity ofNorth lanarkshireDave scottPrnewswire lumiradxSanjay malkaniRon zwanzigerJerry mcaleerLumiradx fastlabLumiradx internationalMedisense incDrug administrationFast lab solutionsMelinda gates foundation

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomNorth lanarkshireUnited statesSouth africaCity ofDave scottNigel lindnerStates marRon zwanzigerColleen mcmillenJerry mcaleerNational health laboratory serviceMedisense incTechnologies validation groupWorld health organizationMelinda gates foundation

LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries

LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomNorth lanarkshireUnited statesCity ofSicherheitsmanagement gmbDave scottMax schmeling halleColleen mcmillenJerry mcaleerArne fritscheRon zwanzigerDavid waltonStefan wielandInverness medical technology incUs boston capital corporationMedisense inc

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing

Share this article Share this article LONDON, Jan. 21, 2021 /PRNewswire/ LumiraDx, the next-generation point-of-care diagnostic testing company, announced today multinational approvals of its SARS-CoV-2 Antigen Test. With approvals in Japan and Brazil, the fast, accurate LumiraDx SARS-CoV-2 Antigen Test is now available to patients in more than 30 nations worldwide. In addition to these authorizations, the Italian Association for Clinical Microbiology recently published testing guidelines favorable to next-generation microfluidic technology – like LumiraDx s – for COVID-19 testing. The LumiraDx SARS-CoV-2 Antigen Test is a microfluidic immunofluorescence assay designed to detect SARS-CoV-2 antigen in nasal or nasopharyngeal swab specimens, with high sensitivity results in 12 minutes from sample application.

United statesUnited kingdomNorth lanarkshireCity ofDave scottRon zwanzigerAsia pacificJerry mcaleerItalian association for clinical microbiologyMedisense incMelinda gates foundationAlere incInverness medical technology incBrazilian health regulatory agencyUs boston capital corporationItalian ministry of health

SKUP kladně hodnotí spolehlivost antigenních testů LumiraDx SARS-CoV-2 u symptomatických i asymptomatických pacientů

SKUP kladně hodnotí spolehlivost antigenních testů LumiraDx SARS-CoV-2 u symptomatických i asymptomatických pacientů
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDave scottMelinda gatesNigel lindnerJerry mcaleerInverness medical technology incLumiradx companyFirm lumiradxAlere incBoston capital corporationCompany lumiradxAre pleasedMiddle eastEmergency useWere ronFirms morningside